Price-file publication check · 45 CFR § 180
B · 85
This hospital's published file contains most of what § 180 requires.
●Machine-readable file published: assessment threshold met
○Gross / standard charges: below assessment threshold
●Discounted cash price: assessment threshold met
●Payer-specific negotiated rates: assessment threshold met
●Min / max negotiated charges: assessment threshold met
●Free, public, no login required: assessment threshold met
Procedures listed
7,059
Insurances with rates
2
CPT / HCPCS codes
4,312
Most expensive procedures (gross)
Q2054
$1,195,548
LISOCABTAGENE MARALEUCEL (CD8) 70000000 CELLS IV SUSP
Gross
$2,656,773
Q2054
$1,195,538
LISOCABTAGENE MARALEUCEL (CD8) 70000000 CELLS IV SUSP
Gross
$2,656,752
Q2055
$1,188,713
IDECABTAGENE VICLEUCEL 460000000 CELLS IV SUSP
Gross
$2,641,583
Q2055
$1,188,713
IDECABTAGENE VICLEUCEL 460000000 CELLS IV SUSP
Gross
$2,641,583
Q2058
$1,181,259
OBECABTAGENE AUTOLEUCEL 10 X 1,000,000 CELLS IV SUSP DAY 0
Gross
$2,625,021
Q2058
$1,181,259
OBECABTAGENE AUTOLEUCEL 100 X 1,000,000 CELLS IV SUSP 50 ML DAY 0
Gross
$2,625,021
Q2042
$377,663
HC KYMRIAH CAR-T CELL-DLBCL
Gross
$839,250
Q2042
$377,663
HC KYMRIAH CAR-T CELL-DLBCL
Gross
$839,250
J1823
$98,251
INEBILIZUMAB-CDON 100 MG/10ML IV SOLN
Gross
$218,335
J1823
$98,251
INEBILIZUMAB-CDON 100 MG/10ML IV SOLN
Gross
$218,335
A9607
$57,420
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN (PLUVICTO) 1000 MBQ/ML IV SOLN
Gross
$127,600
A9607
$57,420
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN (PLUVICTO) 1000 MBQ/ML IV SOLN
Gross
$127,600
J9281
$55,920
MITOMYCIN 80 (2 X 40) MG UL SOLR
Gross
$124,268
J9281
$55,920
MITOMYCIN 80 (2 X 40) MG UL SOLR
Gross
$124,268
J2350
$41,918
OCRELIZUMAB 300 MG/10ML IV SOLN
Gross
$93,151
J2350
$41,918
OCRELIZUMAB 300 MG/10ML IV SOLN
Gross
$93,151
A9543
$41,664
HC PROVSN,THER RADIORX_ZEVAL
Gross
$92,587
A9543
$41,664
HC PROVSN,THER RADIORX_ZEVAL
Gross
$92,587
J9298
$41,412
NIVOLUMAB-RELATLIMAB-RMBW 240-80 MG/20ML IV SOLN
Gross
$92,026
J9298
$41,412
NIVOLUMAB-RELATLIMAB-RMBW 240-80 MG/20ML IV SOLN
Gross
$92,026
J9153
$41,186
DAUNORUBICIN-CYTARABINE LIPO 44-100 MG IV SUSR
Gross
$91,524
J9153
$41,186
DAUNORUBICIN-CYTARABINE LIPO 44-100 MG IV SUSR
Gross
$91,524
J9026
$38,981
TARLATAMAB-DLLE 10 MG IV SOLR
Gross
$86,625
J9029
$35,438
NADOFARAGENE FIRADENOVEC-VNCG 300000000000 VP/ML IS SUSP
Gross
$78,750
J9029
$35,438
NADOFARAGENE FIRADENOVEC-VNCG 300000000000 VP/ML IS SUSP
Gross
$78,750
C2616
$32,973
MICROSPHERES SIR SPHERE
Gross
$73,274
C2616
$32,973
MICROSPHERES SIR SPHERE
Gross
$73,274
J9381
$32,721
TEPLIZUMAB-MZWV 2 MG/2 ML IV SOLN
Gross
$72,713
J9381
$32,721
TEPLIZUMAB-MZWV 2 MG/2 ML IV SOLN
Gross
$72,713
J9311
$31,845
RITUXIMAB-HYALURONIDASE HUMAN 1400-23400 MG -UT/11.7ML SC SOLN
Gross
$70,767
J9311
$31,845
RITUXIMAB-HYALURONIDASE HUMAN 1400-23400 MG -UT/11.7ML SC SOLN
Gross
$70,767
C1820
$30,375
GEN ETERNA 16 CH W/CONT
Gross
$67,500
J9272
$29,864
DOSTARLIMAB-GXLY 500 MG/10ML IV SOLN
Gross
$66,364
J9272
$29,864
DOSTARLIMAB-GXLY 500 MG/10ML IV SOLN
Gross
$66,364
C1778
$29,700
LD NRSTM 75CM 1.3MM
Gross
$66,000
C1787
$28,350
ELITE 7 W CONTRL PROCLAIM
Gross
$63,000
C1787
$28,350
ELITE 7 W CONTRL PROCLAIM
Gross
$63,000
J3241
$27,658
TEPROTUMUMAB-TRBW 500 MG IV SOLR
Gross
$61,463
J3241
$27,658
TEPROTUMUMAB-TRBW 500 MG IV SOLR
Gross
$61,463
J9144
$26,085
DARATUMUMAB-HYALURONIDASE-FIHJ 1800-30000 MG-UT/15ML SC SOLN
Gross
$57,966
J9144
$26,085
DARATUMUMAB-HYALURONIDASE-FIHJ 1800-30000 MG-UT/15ML SC SOLN
Gross
$57,966
J9024
$25,808
ATEZOLIZUMAB-HYALURONIDAS-TQJS 1875-30000 MG-UT/15ML SC SOLN
Gross
$57,351
J9024
$25,808
ATEZOLIZUMAB-HYALURONIDAS-TQJS 1875-30000 MG-UT/15ML SC SOLN
Gross
$57,351
J2329
$24,741
UBLITUXIMAB-XIIY 150 MG/6ML IV SOLN
Gross
$54,981
J2329
$24,741
UBLITUXIMAB-XIIY 150 MG/6ML IV SOLN
Gross
$54,981
J9173
$24,414
DURVALUMAB 500 MG/10ML IV SOLN
Gross
$54,254
J9286
$24,142
GLOFITAMAB-GXBM 10 MG/10ML IV SOLN
Gross
$53,650
J9301
$24,140
OBINUTUZUMAB 1000 MG/40ML IV SOLN
Gross
$53,644
J9301
$24,140
OBINUTUZUMAB 1000 MG/40ML IV SOLN
Gross
$53,644
J9303
$23,564
PANITUMUMAB 400 MG/20ML IV SOLN
Gross
$52,364
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| Q2054 | LISOCABTAGENE MARALEUCEL (CD8) 70000000 CELLS IV SUSP | $2,656,773 | $1,195,548 | — | — | 1 |
| Q2054 | LISOCABTAGENE MARALEUCEL (CD8) 70000000 CELLS IV SUSP | $2,656,752 | $1,195,538 | $531,350 | $1,591,407 | 1 |
| Q2055 | IDECABTAGENE VICLEUCEL 460000000 CELLS IV SUSP | $2,641,583 | $1,188,713 | $528,317 | $1,582,308 | 1 |
| Q2055 | IDECABTAGENE VICLEUCEL 460000000 CELLS IV SUSP | $2,641,583 | $1,188,713 | — | — | 1 |
| Q2058 | OBECABTAGENE AUTOLEUCEL 10 X 1,000,000 CELLS IV SUSP DAY 0 | $2,625,021 | $1,181,259 | $262,500 | $1,572,388 | 1 |
| Q2058 | OBECABTAGENE AUTOLEUCEL 100 X 1,000,000 CELLS IV SUSP 50 ML DAY 0 | $2,625,021 | $1,181,259 | — | — | 1 |
| Q2042 | HC KYMRIAH CAR-T CELL-DLBCL | $839,250 | $377,663 | $167,850 | $839,250 | 1 |
| Q2042 | HC KYMRIAH CAR-T CELL-DLBCL | $839,250 | $377,663 | — | — | 1 |
| J1823 | INEBILIZUMAB-CDON 100 MG/10ML IV SOLN | $218,335 | $98,251 | $519 | $121,176 | 1 |
| J1823 | INEBILIZUMAB-CDON 100 MG/10ML IV SOLN | $218,335 | $98,251 | — | — | 1 |
| A9607 | LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN (PLUVICTO) 1000 MBQ/ML IV SOLN | $127,600 | $57,420 | $240 | $76,432 | 1 |
| A9607 | LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN (PLUVICTO) 1000 MBQ/ML IV SOLN | $127,600 | $57,420 | — | — | 1 |
| J9281 | MITOMYCIN 80 (2 X 40) MG UL SOLR | $124,268 | $55,920 | $333 | $68,968 | 1 |
| J9281 | MITOMYCIN 80 (2 X 40) MG UL SOLR | $124,268 | $55,920 | — | — | 1 |
| J2350 | OCRELIZUMAB 300 MG/10ML IV SOLN | $93,151 | $41,918 | $62.7 | $29,342 | 1 |
| J2350 | OCRELIZUMAB 300 MG/10ML IV SOLN | $93,151 | $41,918 | — | — | 1 |
| A9543 | HC PROVSN,THER RADIORX_ZEVAL | $92,587 | $41,664 | $18,517 | $92,587 | 1 |
| A9543 | HC PROVSN,THER RADIORX_ZEVAL | $92,587 | $41,664 | — | — | 1 |
| J9298 | NIVOLUMAB-RELATLIMAB-RMBW 240-80 MG/20ML IV SOLN | $92,026 | $41,412 | $208 | $51,074 | 1 |
| J9298 | NIVOLUMAB-RELATLIMAB-RMBW 240-80 MG/20ML IV SOLN | $92,026 | $41,412 | — | — | 1 |
| J9153 | DAUNORUBICIN-CYTARABINE LIPO 44-100 MG IV SUSR | $91,524 | $41,186 | $268 | $50,796 | 1 |
| J9153 | DAUNORUBICIN-CYTARABINE LIPO 44-100 MG IV SUSR | $91,524 | $41,186 | — | — | 1 |
| J9026 | TARLATAMAB-DLLE 10 MG IV SOLR | $86,625 | $38,981 | — | — | 1 |
| J9029 | NADOFARAGENE FIRADENOVEC-VNCG 300000000000 VP/ML IS SUSP | $78,750 | $35,438 | $15,750 | $78,750 | 1 |
| J9029 | NADOFARAGENE FIRADENOVEC-VNCG 300000000000 VP/ML IS SUSP | $78,750 | $35,438 | — | — | 1 |
| C2616 | MICROSPHERES SIR SPHERE | $73,274 | $32,973 | $23,081 | $29,310 | 1 |
| C2616 | MICROSPHERES SIR SPHERE | $73,274 | $32,973 | $14,655 | $43,891 | 1 |
| J9381 | TEPLIZUMAB-MZWV 2 MG/2 ML IV SOLN | $72,713 | $32,721 | $39.54 | $40,355 | 1 |
| J9381 | TEPLIZUMAB-MZWV 2 MG/2 ML IV SOLN | $72,713 | $32,721 | — | — | 1 |
| J9311 | RITUXIMAB-HYALURONIDASE HUMAN 1400-23400 MG -UT/11.7ML SC SOLN | $70,767 | $31,845 | $38.82 | $39,276 | 1 |
| J9311 | RITUXIMAB-HYALURONIDASE HUMAN 1400-23400 MG -UT/11.7ML SC SOLN | $70,767 | $31,845 | — | — | 1 |
| C1820 | GEN ETERNA 16 CH W/CONT | $67,500 | $30,375 | $21,263 | $27,000 | 1 |
| J9272 | DOSTARLIMAB-GXLY 500 MG/10ML IV SOLN | $66,364 | $29,864 | $256 | $36,832 | 1 |
| J9272 | DOSTARLIMAB-GXLY 500 MG/10ML IV SOLN | $66,364 | $29,864 | — | — | 1 |
| C1778 | LD NRSTM 75CM 1.3MM | $66,000 | $29,700 | $158 | $39,534 | 1 |
| C1787 | ELITE 7 W CONTRL PROCLAIM | $63,000 | $28,350 | $714 | $37,737 | 1 |
| C1787 | ELITE 7 W CONTRL PROCLAIM | $63,000 | $28,350 | — | — | 1 |
| J3241 | TEPROTUMUMAB-TRBW 500 MG IV SOLR | $61,463 | $27,658 | $377 | $34,112 | 1 |
| J3241 | TEPROTUMUMAB-TRBW 500 MG IV SOLR | $61,463 | $27,658 | — | — | 1 |
| J9144 | DARATUMUMAB-HYALURONIDASE-FIHJ 1800-30000 MG-UT/15ML SC SOLN | $57,966 | $26,085 | $57.41 | $32,171 | 1 |
| J9144 | DARATUMUMAB-HYALURONIDASE-FIHJ 1800-30000 MG-UT/15ML SC SOLN | $57,966 | $26,085 | — | — | 1 |
| J9024 | ATEZOLIZUMAB-HYALURONIDAS-TQJS 1875-30000 MG-UT/15ML SC SOLN | $57,351 | $25,808 | $33.22 | $31,830 | 1 |
| J9024 | ATEZOLIZUMAB-HYALURONIDAS-TQJS 1875-30000 MG-UT/15ML SC SOLN | $57,351 | $25,808 | — | — | 1 |
| J2329 | UBLITUXIMAB-XIIY 150 MG/6ML IV SOLN | $54,981 | $24,741 | $75.51 | $30,514 | 1 |
| J2329 | UBLITUXIMAB-XIIY 150 MG/6ML IV SOLN | $54,981 | $24,741 | — | — | 1 |
| J9173 | DURVALUMAB 500 MG/10ML IV SOLN | $54,254 | $24,414 | $89.53 | $30,111 | 1 |
| J9286 | GLOFITAMAB-GXBM 10 MG/10ML IV SOLN | $53,650 | $24,142 | — | — | 1 |
| J9301 | OBINUTUZUMAB 1000 MG/40ML IV SOLN | $53,644 | $24,140 | $82.4 | $16,898 | 1 |
| J9301 | OBINUTUZUMAB 1000 MG/40ML IV SOLN | $53,644 | $24,140 | — | — | 1 |
| J9303 | PANITUMUMAB 400 MG/20ML IV SOLN | $52,364 | $23,564 | — | — | 1 |
Showing top 50 of 7,059 priced procedures, sorted by gross charge.
Data straight from this hospital's own published price file (45 CFR § 180). The grade scores how completely the file contains the six required data elements. It is a check of the file — not a CMS compliance ruling, and not a measure of quality of care.